Brief: Nicox Q2 Revenue At 700 Thousand Euros

Nicox SA

16/07/2021 06:45

July 16 (Reuters) - NICOX SA  NCOX.PA :
    * Q2 REVENUE EUR 700,000
    * VYZULTA AND ZERVIATE PRESCRIPTIONS IN U.S. INCREASED BY
21% AND
712% RESPECTIVELY IN Q2 2021 COMPARED TO Q2 2020
    * CASH OF EUR 36.5 MILLION ON JUNE 30, 2021 SUFFICIENT FOR
COMPANY
TO MEET ITS CURRENT REQUIREMENTS FOR NEXT TWELVE MONTHS
    * AS OF JUNE 30, 2021, NICOX GROUP HAD FINANCIAL DEBT OF EUR
18.0
MILLION
    * NCX 4251 TOP-LINE RESULTS EXPECTED IN SEPTEMBER 2021
    * NEXT STEPS IN DEVELOPMENT OF NCX 4251, NOT CURRENTLY
FINANCED,
TO BE ANNOUNCED AFTER END-PHASE 2 MEETING WITH FDA, EXPECTED
START OF 2022
    * NCX 470  IS CURRENTLY IN TWO MULTI-REGIONAL PHASE 3
GLAUCOMA
CLINICAL TRIALS, WITH TOP-LINE RESULTS FROM THE FIRST PHASE 3
CLINICAL TRIAL, MONT BLANC, EXPECTED IN Q2 2022
    * NCX 470 : RESULTS FROM THE SECOND PHASE 3 TRIAL, DENALI,
ARE
EXPECTED IN 2023
    * OUR MARKET RESEARCH SUGGESTS PEAK NET SALES POTENTIAL FOR
NCX
470 IN U.S. OF OVER $500 MILLION, IF APPROVED AND DEPENDING ON
RESULTS OF PHASE 3 CLINICAL TRIALS

Source text for Eikon:  ID:nGNX8dTwXV 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))